MU Department of Medicine 2011-2013 Annual Report Feb. 2014

2011-2013 Department of Medicine 63 Hardy Trust, $26,750, 01/01/2011 to Safety of Baricitinib(LY3009104) in metabolic signaling, Department 12/31/2012 Patients with Inadequate Response of Veterans’ Affairs, $650,000, to Conventional Disease-Modifying 10/01/2008 to 09/30/2012 Principal Investigator Antirheumatic Drugs with Moderately/ Thyroid Epithelial Cell Hyperplasia: Severely Active RA, Eli Lilly, $58,838, Co-Investigator Mechanisms of Induction, National 02/01/2013 to 01/31/2015 Impact of Saxagliptin Therapy on Institutes of Health, $717,294, Angiotensin II-dependent Salt- 07/01/2011 to 06/30/2014 sensative Hypertension, Bristol Myers Role of T cells and cytokines in nephrology + Hypertension autoimmune diseases, Lottie of Adam Whaley-Connell, DO Caroline Hardy Trust, $30,000, Principal Investigator 01/01/2012 to 12/31/2014 The role of angiotensin II on mTOR Principal Investigator Squibb, $268,096, 03/01/2013 to 02/28/2014 Chokkalingam Siva, MD NIH NIA, $146,350, 08/01/2011 to pulmonary, critical care + environmental medicine Principal Investigator 07/30/2013 Vamsi Gunter, MD mediated tubulointerstitial fibrosis, A Multicenter, randomized, double- Principal Investigator blind, long term study of the safety Principal Investigator Airway Epithelium Gene Expression in of subcutaneous administration Junior Development Grant in the diagnosis of Lung Cancer, Allegro of Tanezumab in patients with Nephrology, American Society of Diagnostics, $59,000, 03/04/2009 to Osteoarthritis of the knee or hip, Pfizer, Nephrology, $50,000, 08/01/2011 to 03/31/2013 $96,145, 10/08/2009 to 07/01/2013 07/30/2013 Principal Investigator Principal Investigator Detection of lung tumors in mice A long-term follow-up study of Angiotensin-II and aldosterone using targeted nanoparticles, Research CP-690,550, a moderately selective mediated renal insulin resistance, Council, $7,478, 06/01/2010 to Janus-Kinase-3 inhibitor for the VA Career Development Award-2 11/30/2012 treatment of rheumatoid arthritis, 047-09S Department of Veteran’s Pfizer, $33,341.90, 08/18/2009 to Affairs, $1,124,581, 10/01/2009 to Co- Investigator 08/31/2014 09/30/2013 Biomarkers in exhaled breath Principal Investigator Co-Principal Investigator treated with glucocorticoid, Morris Lilly-Protocol 14V-MC-JADV A Ang II opposes insulin mediated Animal Foundation Pilot Study Randomized, Double-Blind, Placebo vasorelaxation and glucose utilization, Program, $10,800, 10/01/2010 to and Active-Controlled, Phase 3 NIH/NHLBI $1,125,000, 04/01/2009 to 09/30/2011 Study Evaluating the Efficacy/ 03/30/2014 Principal Investigator condensate with allergic asthma Safety of Baricitinib in Patients with Harjyot Sohal, MD Moderately to Severely

MU Department of Medicine 2011-2013 Annual Report Feb. 2014 | Page 63